Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Piramal Pharma Limited (NSE: PPLPHARMA), ISIN INE0DK501011 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
PPLPHARMA last traded at ₹247.20 (+3.29%), with a 52-week range of ₹132.30 to ₹250.40 (as of 6 Nov 2026).
Shareholding as of Sep 2026: promoters 34.80%, FIIs 13.65%, DIIs 14.43%, mutual funds 12.71%.
EquiSense Score (ECS): 74/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.